Of a combined 255 treatment-naïve and previously treated subjects from Trials 108, 111, and C216 in whom telaprevir-resistant
variants had emerged during treatment, 103 (40%) had detectable resistant
variants by population sequencing at end of trial (follow-up range 2-70 weeks, median 45 weeks) and results for loss of variants were similar across the three trials.